{
    "address": "Medicon Village, Scheelevagen 2",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4R43N205",
    "description": "Idogen AB engages in the research and development for the treatment of diseases including autoimmune disease and transplant rejection. The company is headquartered in Lund, Skane. The company went IPO on 2015-06-12. The firm is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given back to the patient. The firm is in pre-clinical phase and owns a platform technology, from which Idogen AB develops treatment for anti-drug antibodies, as well as autoimmune diseases that cannot be cured. In addition, the Company focuses on the transplantation market by reducing the need for immunosuppressive therapy after transplantation.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2015-06-12",
    "isin": "SE0014428561",
    "logo": "",
    "marketCapitalization": 63.57793,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Idogen AB",
    "phone": "46462756330.0",
    "sedol": "BL58ZX3",
    "shareOutstanding": 18.243308,
    "state": "SKANE",
    "ticker": "IDOGEN.ST",
    "weburl": "https://idogen.com/"
}